Non-small cell lung cancer metastatic

72 trials 20 recruiting MedDRA PT
72 Registered trials
20 Recruiting
43 Unique sponsors
76 Unique IMPs
64 Commercial trials
Drug classes (ATC)
— ATC code not specified 32
L Oncology (ATC L) 34
N Neurology/Psychiatry (ATC N) 5
A Gastroenterology (ATC A) 3
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 42 substances
Monoclonal antibody (immune) 4 substances
Taxane 3 substances
Kinase inhibitor 3 substances
Checkpoint inhibitor (PD-L1) 2 substances
Antibody-drug conjugate (ADC) 2 substances
Checkpoint inhibitor (CTLA-4) 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Antimetabolite 2 substances
Monoclonal antibody (human) 2 substances
Platinum compound 2 substances
Monoclonal antibody (chimeric) 2 substances
Monoclonal antibody (tumor, humanized) 2 substances
Immunosuppressant 1 substance
Corticosteroid 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody (primate) 1 substance
Monoclonal antibody (angiogenesis) 1 substance
DPP-4 inhibitor 1 substance
Phase III: 27 Phase II/III: 3 Phase II: 14 Phase I/II: 15 Phase IV: 1 Phase I: 4 Phase I (Other): 4 Phase I (First in Human): 4

Filter these 72 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 72 trials

Phase III

27 trials
  • AstraZeneca AB Commercial
    CARBOPLATIN; INFLIXIMAB; MYCOPHENOLATE MOFETIL; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; VOLRUSTOMIG
    2023-503298-39-00 11 countries 2024 n=437
    Halted
  • AstraZeneca AB Commercial
    CERALASERTIB; DOCETAXEL; DURVALUMAB; INFLIXIMAB; MYCOPHENOLATE MOFETIL
    2023-509429-37-00 10 countries 2022 n=520
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    ADAGRASIB
    2024-515698-85-00 15 countries 2025 n=257
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    PUMITAMIG
    2025-523586-18-00 16 countries n=265
    Pending
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN
    2023-506330-73-00 4 countries 2024 n=64
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; TIRAGOLUMAB
    2022-502482-17-00 8 countries 2020 n=192
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2024-510908-37-00 13 countries 2024 n=250
    Ended
  • F. Hoffmann-La Roche AG Commercial
    BUDESONIDE; CARBOPLATIN; CISPLATIN; DIVARASIB; PEMBROLIZUMAB; PEMETREXED
    2024-518365-10-00 12 countries 2025 n=282
    Recruiting
  • Formycon AG Commercial
    PEMBROLIZUMAB
    2023-509766-37-00 3 countries n=81
    Ended
  • Genmab A/S Commercial
    ACASUNLIMAB; MYCOPHENOLATE MOFETIL; PEMBROLIZUMAB; TOCILIZUMAB
    2024-512998-27-00 15 countries 2025 n=398
    Ended
  • Immutep Commercial
    EFTILAGIMOD ALFA; PEMBROLIZUMAB; PEMETREXED
    2024-513621-23-00 15 countries 2025 n=363
    Ended
  • Merck Sharp & Dohme LLC Commercial
    CARBOPLATIN; CISPLATIN; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; PEMETREXED
    2022-501506-36-00 5 countries 2023 n=100
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB; SACITUZUMAB TIRUMOTECAN
    2023-503376-24-00 9 countries 2024 n=196
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-503501-11-00 8 countries 2023 n=153
    Ended
  • Merck Sharp & Dohme LLC Commercial
    SACITUZUMAB TIRUMOTECAN
    2023-503539-16-00 7 countries 2025 n=107
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; PEMBROLIZUMAB, VIBOSTOLIMAB; PEMETREXED
    2023-506074-12-00 5 countries 2022 n=190
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-508308-40-00 5 countries 2021 n=215
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2024-513165-39-00 4 countries 2024 n=46
    Ended
  • Oncoc4 Inc. Commercial
    DOCETAXEL; HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST CD152
    2023-505311-20-00 4 countries n=110
    Not authorised
  • Oncoc4 Inc. Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST CD152
    2023-505311-20-01 5 countries 2025 n=100
    Recruiting
  • Pfizer Inc. Commercial
    IMP not specified
    2023-509169-19-00 8 countries 2017 n=33
    Ended
  • Pfizer Inc. Commercial
    PF-08634404
    2025-523461-17-01 8 countries n=387
    Pending
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2024-515101-26-00 1 country 2020 n=1
    Ended
  • Summit Therapeutics Inc. Commercial
    CARBOPLATIN; IVONESCIMAB; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; PEMETREXED
    2024-513087-26-00 9 countries 2024 n=661
    Recruiting
  • Summit Therapeutics Sub Inc. Commercial
    CARBOPLATIN; IVONESCIMAB; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB
    2023-504989-37-00 7 countries n=135
    Not authorised
  • Xcovery Holding Co. LLC Commercial
    CRIZOTINIB; X-396
    2024-513454-29-00 7 countries 2015 n=47
    Ended
  • Yuhan Corp. Commercial
    GEFITINIB; LAZERTINIB
    2024-514771-18-00 2 countries 2020 n=5
    Ended

Phase II/III

3 trials
  • AstraZeneca AB Commercial
    CERALASERTIB; DURVALUMAB; TRASTUZUMAB DERUXTECAN
    2023-509004-15-00 4 countries 2018 n=172
    Ended
  • BioNTech SE Commercial
    BISPECIFIC ANTIBODY AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR A AND PROGRAMMED DEATH-LIGAND 1; BNT327
    2024-515764-31-00 9 countries 2025 n=726
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    2025-521511-40-00 15 countries 2025 n=191
    Recruiting

Phase II

14 trials
  • Bicycletx Limited Commercial
    ZELENECTIDE PEVEDOTIN
    2025-521115-40-00 4 countries 2025 n=28
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IPILIMUMAB; NIVOLUMAB
    2024-520108-25-00 5 countries 2025 n=40
    Ended
  • Celgene Corp. Commercial
    AZACITIDINE
    2024-513405-31-00 1 country 2015 n=1
    Ended
  • Genentech Inc. Commercial
    ATEZOLIZUMAB; TIRAGOLUMAB
    2023-508083-30-00 2 countries 2018 n=47
    Ended
  • Genmab A/S Commercial
    RINATABART SESUTECAN
    2025-522107-18-00 8 countries 2026 n=109
    Recruiting
  • Incyte Corp. Commercial
    INCB099280
    2022-502716-37-00 3 countries 2023 n=70
    Ended
  • IO Biotech ApS Commercial
    IO103 ACETATE; PEMBROLIZUMAB
    2024-511561-10-00 1 country 2022 n=38
    Ended
  • iTeos Belgium Commercial
    INUPADENANT HYDROCHLORIDE
    2024-515393-27-00 6 countries n=131
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB, VIBOSTOLIMAB
    2022-501252-28-00 9 countries 2021 n=150
    Ended
  • Mirati Therapeutics Inc. Commercial
    ADAGRASIB
    2023-503523-25-00 9 countries 2024 n=267
    Recruiting
  • Seagen Inc. Commercial
    PEMBROLIZUMAB; TISOTUMAB VEDOTIN
    2023-503812-34-00 4 countries 2019 n=79
    Ended
  • ETOP IBCSG Partners Foundation Academic
    DURVALUMAB; TREMELIMUMAB
    2024-511134-12-00 3 countries 2023 n=28
    Ended
  • Institut De Cancerologie De L Ouest Academic
    FLUORODOPA (18F)
    2024-515850-26-00 1 country 2021 n=52
    Ended
  • Unicancer Academic
    CEMIPLIMAB; PEMBROLIZUMAB
    2025-522655-26-00 1 country n=55
    Pending

Phase I/II

15 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BUDIGALIMAB; CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; PEMETREXED; TELISOTUZUMAB ADIZUTECAN
    2024-514465-18-00 7 countries 2025 n=96
    Recruiting
  • AstraZeneca AB Commercial
    RAMUCIRUMAB; RILVEGOSTOMIG
    2024-519786-22-01 7 countries n=56
    Pending
  • BioNTech SE Commercial
    BNT326; BNT327
    2024-519344-32-00 4 countries 2026 n=88
    Recruiting
  • BioNTech SE Commercial
    BNT324; BNT327
    2024-520238-31-01 4 countries 2026 n=112 Orphan
    Recruiting
  • Cullinan Pearl Corp. Commercial
    CLN-081
    2024-516532-97-00 3 countries 2020 n=63
    Ended
  • Daiichi Sankyo Inc. Commercial
    PEMBROLIZUMAB; VALEMETOSTAT TOSILATE
    2024-519671-26-00 3 countries n=21
    Ended
  • Ellipses Pharma Limited Commercial
    EP0031
    2022-501636-42-00 5 countries 2023 n=127 Orphan
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; BEVACIZUMAB; CAMONSERTIB; DOCETAXEL; LINAGLIPTIN
    2023-504038-23-00 2 countries 2018 n=149
    Ended
  • F. Hoffmann-La Roche AG Commercial
    BUDESONIDE; CARBOPLATIN; CISPLATIN; DIVARASIB; PEMBROLIZUMAB; PEMETREXED
    2023-507171-22-00 6 countries 2023 n=116
    Recruiting
  • Incyte Corp. Commercial
    ADAGRASIB; INCB099280
    2023-503223-26-00 3 countries 2024 n=75
    Ended
  • Institut De Recherches Internationales Servier IRIS Commercial
    CEMIPLIMAB; SYM023; SYM024; SYM025
    2023-508730-34-00 7 countries 2024 n=93
    Halted
  • iOnctura SA Commercial
    ANHYDROUS DOCETAXEL; DOSTARLIMAB; ROGINOLISIB
    2024-517741-14-00 3 countries 2025 n=51
    Ended
  • Merck Healthcare KGaA Commercial
    PRECEMTABART TOCENTECAN
    2024-517818-15-00 5 countries 2025 n=51
    Ended
  • Pfizer Inc. Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST PD-L1 CONJUGATED TO MONOMETHYL AURISTATIN E VIA A VALINE-CITRULLINE LINKER; PF-08634404; SIGVOTATUG VEDOTIN
    2025-523526-40-00 4 countries n=53
    Pending
  • Zhejiang Genfleet Therapeutics Co. Ltd. Academic
    CETUXIMAB; GFH925
    2022-501451-87-00 3 countries 2023 n=32
    Ended

Phase IV

1 trial
  • Amphia Hospital Academic
    CALCIUM FOLINATE
    2022-502345-10-00 1 country 2023 n=50
    Ended

Phase I

4 trials
  • BeOne Medicines AG Commercial
    IMP not specified
    2024-515307-19-00 3 countries 2025 n=79
    Recruiting
  • Transgene Commercial
    IMP not specified
    2024-513093-22-00 1 country 2023 n=36
    Ended
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended
  • Universitair Ziekenhuis Gent Academic
    CARBOPLATIN; CEMIPLIMAB; CISPLATIN; MIDRIX-LUNG-001; MIDRIX-LUNG-002; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED
    2025-521577-13-00 1 country n=64
    Pending

Phase I (Other)

4 trials
  • Arrivent Biopharma Inc. Commercial
    IMP not specified
    2023-508349-42-00 4 countries 2022 n=32
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2024-511030-12-00 3 countries 2025 n=17
    Ended
  • Systimmune Inc. Commercial
    IMP not specified
    2023-506539-14-00 3 countries 2025 n=95
    Recruiting
  • Instituto Oncologico Dr. Rosell S.L. Academic
    IMP not specified
    2023-509776-41-00 1 country 2021 n=48
    Ended

Phase I (First in Human)

4 trials
  • Achilles Therapeutics UK Limited Commercial
    ATL001; PEMBROLIZUMAB
    2024-513060-26-00 3 countries 2021 n=24
    Ended
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Pfizer Inc. Commercial
    PF-07220060 MONOHYDRATE
    2024-512120-11-00 2 countries 2022 n=62
    Ended
  • Pierre Fabre Medicament Commercial
    STX-241
    2023-510203-21-00 4 countries 2024 n=66
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Merck Sharp & Dohme LLC Commercial 8 Phase II, Phase III 1
Bristol-Myers Squibb Services Unlimited Company Commercial 5 Phase II/III, Phase I (Other), Phase II, Phase III 2
F. Hoffmann-La Roche AG Commercial 5 Phase III, Phase I/II 2
AstraZeneca AB Commercial 4 Phase II/III, Phase III, Phase I/II 0
Pfizer Inc. Commercial 4 Phase III, Phase I (First in Human), Phase I/II 0
BioNTech SE Commercial 3 Phase II/III, Phase I/II 3
Incyte Corp. Commercial 3 Phase II, Phase I/II, Phase I 0
Daiichi Sankyo Inc. Commercial 3 Phase III, Phase I (First in Human), Phase I/II 2
Genmab A/S Commercial 2 Phase II, Phase III 1
Oncoc4 Inc. Commercial 2 Phase III 1
BeOne Medicines AG Commercial 1 Phase I 1
Transgene Commercial 1 Phase I 0
Arrivent Biopharma Inc. Commercial 1 Phase I (Other) 1
Systimmune Inc. Commercial 1 Phase I (Other) 1
Bicycletx Limited Commercial 1 Phase II 0
Celgene Corp. Commercial 1 Phase II 0
Genentech Inc. Commercial 1 Phase II 0
IO Biotech ApS Commercial 1 Phase II 0
iTeos Belgium Commercial 1 Phase II 0
Mirati Therapeutics Inc. Commercial 1 Phase II 1
New trials by year
2019
1
2020
4
2021
5
2022
6
2023
9
2024
10
2025
17
2026
3
← All indication landscapes